nderstanding the biology of ETP-ALL.
Not Applicable
- Conditions
- Health Condition 1: C948- Other specified leukemias
- Registration Number
- CTRI/2022/03/041157
- Lead Sponsor
- ady Tata Memorial Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Study Population
Inclusion Criteria are following three
Age greater than equal to 15 years
Newly diagnosed cases of ETP ALL and T cell ALL
Planned for systematic therapy
Exclusion Criteria
Exclusion Criteria are following two points
Any previous treatment received
Unfit for treatment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective 1: To demonstrate prednisolone resistance and its biological basis in ETP-ALL compared to non ETP subtype of T ALL and to evaluate the impact of prednisolone exposure on the chemosensitivity to other <br/ ><br>drugs used in ALL induction therapy. <br/ ><br>Objective 2: To demonstrate the exquisite sensitivity of ETP- ALL to 6-MP as compared to other ALL <br/ ><br>subtypes and its underlying biological basis. <br/ ><br>Objective 3: In-vitro and in-vivo validation of sensitivity of ETP-ALL to FDA approved drugs as predicted by <br/ ><br>in-silico analysis.Timepoint: 4 years
- Secondary Outcome Measures
Name Time Method oneTimepoint: 0